1. Home
  2. RAND vs NOTV Comparison

RAND vs NOTV Comparison

Compare RAND & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rand Capital Corporation

RAND

Rand Capital Corporation

N/A

Current Price

$12.15

Market Cap

32.4M

Sector

Finance

ML Signal

N/A

Logo Inotiv Inc.

NOTV

Inotiv Inc.

N/A

Current Price

$0.42

Market Cap

12.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RAND
NOTV
Founded
1969
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.4M
12.7M
IPO Year
1996
1997

Fundamental Metrics

Financial Performance
Metric
RAND
NOTV
Price
$12.15
$0.42
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
3.3K
553.8K
Earning Date
06-01-2026
05-14-2026
Dividend Yield
9.87%
N/A
EPS Growth
N/A
49.64
EPS
N/A
N/A
Revenue
N/A
$547,656,000.00
Revenue This Year
N/A
$5.28
Revenue Next Year
N/A
$5.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
511.19
52 Week Low
$10.05
$0.25
52 Week High
$26.00
$3.35

Technical Indicators

Market Signals
Indicator
RAND
NOTV
Relative Strength Index (RSI) 59.64 57.99
Support Level $10.56 $0.26
Resistance Level $12.50 $0.65
Average True Range (ATR) 0.41 0.04
MACD 0.13 0.03
Stochastic Oscillator 93.29 80.60

Price Performance

Historical Comparison
RAND
NOTV

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: